-
Product Insights
Eosinophilia – Drugs In Development, 2023
Global Markets Direct’s, ‘Eosinophilia - Drugs In Development, 2023’, provides an overview of the Eosinophilia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Eosinophilia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Hypereosinophilic Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypereosinophilic Syndrome - Drugs In Development, 2023’, provides an overview of the Hypereosinophilic Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Atopic Keratoconjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Atopic Keratoconjunctivitis - Drugs In Development, 2023’, provides an overview of the Atopic Keratoconjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atopic Keratoconjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Allergic Conjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Conjunctivitis - Drugs In Development, 2023’, provides an overview of the Allergic Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Conjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Conjunctivitis - Drugs In Development, 2023’, provides an overview of the Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Leukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leukocyte Disorders (White Blood Cell Disorders) - Drugs In Development, 2023’, provides an overview of the Leukocyte Disorders (White Blood Cell Disorders) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leukocyte Disorders (White Blood Cell Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Keratoconjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Hypereosinophilic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (≥ 1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical eosinophilia, or cancer) have been ruled out. The Hypereosinophilic Syndrome pipeline drugs market research report provides...
-
Product Insights
Asthma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Asthma, a chronic disease involving the airways in the lungs, may occur with symptoms that include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The Asthma pipeline drugs market research report outlays comprehensive information on the Asthma targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by companies/universities. It also reviews key players involved in...
-
Product Insights
Eosinophilic Esophagitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis – Drugs In Development, 2022, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape. Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and...